10-K - REGENXBIO Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

REGENXBIO Inc. reported total revenues of $170.4 million for FY 2025, a significant increase from $83.3 million in FY 2024, driven by a $74.3 million increase in license and royalty revenue primarily from a $72.9 million up-front license fee under the Nippon Shinyaku collaboration and a $1.7 million increase in Zolgensma/Itvisma royalties. Despite revenue growth, the company incurred a net loss of $193.9 million, an improvement from a $227.1 million loss in FY 2024, as increased operating expenses ($331.6 million vs. $316.7 million) and higher interest expense ($45.0 million vs. $12.7 million) were partially offset by revenue gains. The company ended the year with $240.9 million in cash, cash equivalents, and marketable securities, which management estimates will fund operations into early 2027, though substantial doubt exists about its ability to continue as a going concern beyond that point without additional capital or successful product commercialization.

Key Takeaways

1Total revenues increased 104% YoY to $170.4M, driven by a $72.9M Nippon Shinyaku up-front fee.

2Net loss improved to $193.9M from $227.1M prior year, despite higher interest expense of $45.0M.

3Cash, cash equivalents, and marketable securities totaled $240.9M, estimated to fund operations into early 2027.

4Zolgensma and Itvisma royalties increased to $83.2M from $81.5M, on Novartis sales of $1.23B.

5Research and development expenses increased to $228.3M, with direct costs for ABBV-RGX-314 at $37.6M.

Key Financial Metrics

EPS

-$4.00

Not provided for prior year

Revenue

$170.4M

+104%

Net Income

-$193.9M

+15%

Gross Margin

88.1%

59.7% prior year

Business Segments

License and Royalty RevenueIncludes $72.9M Nippon Shinyaku up-front fee and $83.2M Zolgensma/Itvisma royalties

$156.3M+91% YoY

Service RevenuePrimarily from RGX-121 development and manufacturing services for Nippon Shinyaku

$14.2M+936% YoY